Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/effect-of-modified-vaccinia-ankara-5t4-and-low-dose-cyclophosphamide-2JbYUUG0xT
References (32)
-
V. Radojcic, K. Bezak, Mario Škarica, M. Pletneva, K. Yoshimura, R. Schulick, L. Luznik (2009)
Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell eliminationCancer Immunology, Immunotherapy, 59
-
D. Le, E. Jaffee (2012)
Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective.Cancer research, 72 14
-
T. Simpson, Fubin Li, Welby Montalvo-Ortiz, Manuel Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J. Henry, H. Yagita, J. Wolchok, K. Peggs, J. Ravetch, J. Allison, S. Quezada (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanomaThe Journal of Experimental Medicine, 210
-
G. Kroemer, L. Galluzzi, L. Zitvogel, W. Fridman (2015)
Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?OncoImmunology, 4
-
(2007)
chemotherapyinducespotentimmuneresponses -
F. Ghiringhelli, C. Ménard, P. Puig, S. Ladoire, S. Roux, F. Martin, E. Solary, A. Cesne, L. Zitvogel, B. Chauffert (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 56
-
J. Hindley, E. Jones, K. Smart, Hayley Bridgeman, S. Lauder, B. Ondondo, Scott Cutting, K. Ladell, Katherine Wynn, D. Withers, D. Price, A. Ager, A. Godkin, A. Gallimore (2012)
T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion.Cancer research, 72 21
-
E. Quoix, H. Léna, G. Losonczy, F. Forget, C. Chouaid, Z. Pápai, R. Gervais, C. Ottensmeier, A. Szczesna, A. Każarnowicz, J. Beck, V. Westeel, E. Felip, D. Debieuvre, A. Madroszyk, J. Adam, G. Lacoste, A. Tavernaro, B. Bastien, C. Halluard, T. Palanché, J. Limacher (2016)
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.The Lancet. Oncology, 17 2
-
M. Scurr, Anja Bloom, T. Pembroke, R. Srinivasan, C. Brown, K. Smart, Hayley Bridgeman, M. Davies, R. Hargest, S. Phillips, A. Christian, T. Hockey, A. Gallimore, A. Godkin (2013)
Escalating Regulation of 5T4-Specific IFN-γ+ CD4+ T Cells Distinguishes Colorectal Cancer Patients from Healthy Controls and Provides a Target for In Vivo TherapyCancer Immunology Research, 1
-
D. Frey, R. Droeser, C. Viehl, I. Zlobec, A. Lugli, U. Zingg, D. Oertli, C. Kettelhack, L. Terracciano, L. Tornillo (2010)
High frequency of tumor‐infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair‐proficient colorectal cancer patientsInternational Journal of Cancer, 126
-
G. Betts, E. Jones, S. Junaid, T. El-shanawany, M. Scurr, P. Mizen, Mayur Kumar, Sion Jones, Brian Rees, Geraint Williams, A. Gallimore, A. Godkin (2011)
Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancerGut, 61
-
R. Amato, R. Hawkins, H. Kaufman, John Thompson, P. Tomczak, C. Szczylik, M. Mcdonald, S. Eastty, W. Shingler, J. Belin, M. Goonewardena, S. Naylor, R. Harrop (2010)
Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III StudyClinical Cancer Research, 16
-
R. Harrop, N. Drury, W. Shingler, P. Chikoti, Irina Redchenko, M. Carroll, S. Kingsman, S. Naylor, A. Melcher, J. Nicholls, H. Wassan, N. Habib, A. Anthoney (2007)
Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune ResponsesClinical Cancer Research, 13
-
C. Fitzmaurice, Christine Allen, Ryan Barber, L. Barregard, Z. Bhutta, H. Brenner, D. Dicker, Odgerel Chimed-Orchir, R. Dandona, L. Dandona, T. Fleming, M. Forouzanfar, Jamie Hancock, Roderick Hay, Rachel Hunter-Merrill, Chantal Huynh, H. Hosgood, C. Johnson, J. Jonas, J. Khubchandani, G. Kumar, Michael Kutz, Q. Lan, H. Larson, Xiaofeng Liang, Stephen Lim, Alan Lopez, Michael MacIntyre, L. Marczak, N. Marquez, A. Mokdad, Christine Pinho, F. Pourmalek, J. Salomon, J. Sanabria, Logan Sandar, B. Sartorius, S. Schwartz, K. Shackelford, K. Shibuya, J. Stanaway, C. Steiner, Jiandong Sun, Ken Takahashi, S. Vollset, T. Vos, Joseph Wagner, Haidong Wang, R. Westerman, H. Zeeb, Leo Zoeckler, F. Abd-Allah, M. Ahmed, S. Alabed, N. Alam, S. Aldhahri, Girma Alem, Mulubirhan Alemayohu, R. Ali, Rajaa Al-Raddadi, Azmeraw Amare, Y. Amoako, A. Artaman, H. Asayesh, N. Atnafu, A. Awasthi, H. Saleem, A. Barać, Neeraj Bedi, I. Benseñor, A. Berhane, E. Bernabé, B. Betsu, A. Binagwaho, D. Boneya, Ismael Campos-Nonato, C. Castañeda-Orjuela, F. Catalá-López, P. Chiang, C. Chibueze, Abdulaal Chitheer, J. Choi, B. Cowie, S. Damtew, J. Neves, S. Dey, S. Dharmaratne, P. Dhillon, E. Ding, T. Driscoll, D. Ekwueme, A. Endries, M. Farvid, F. Farzadfar, João Fernandes, F. Fischer, Tsegaye G/hiwot, A. Gebru, S. Gopalani, A. Hailu, M. Horino, N. Horita, A. Husseini, I. Huybrechts, M. Inoue, F. Islami, M. Jakovljevic, S. James, Mehdi Javanbakht, S. Jee, A. Kasaeian, Muktar Kedir, Y. Khader, Y. Khang, Daniel Kim, J. Leigh, S. Linn, R. Lunevicius, Hassan Razek, R. Malekzadeh, D. Malta, W. Marcenes, D. Markos, Y. Melaku, K. Meles, W. Mendoza, Desalegn Mengiste, T. Meretoja, T. Miller, K. Mohammad, A. Mohammadi, S. Mohammed, M. Moradi-Lakeh, G. Nagel, D. Nand, Q. Nguyen, Sandra Nolte, F. Ogbo, K. Oladimeji, Eyal Oren, Mahesh Pa, Eun‐Kee Park, David Pereira, D. Plass, M. Qorbani, A. Radfar, Anwar Rafay, Mahfuzar Rahman, S. Rana, K. Søreide, Maheswar Satpathy, M. Sawhney, S. Sepanlou, M. Shaikh, Jun She, I. Shiue, H. Shore, M. Shrime, S. So, S. Soneji, V. Stathopoulou, K. Stroumpoulis, M. Sufiyan, Bryan Sykes, R. Tabarés-Seisdedos, Fentaw Tadese, B. Tedla, G. Tessema, J. Thakur, B. Tran, K. Ukwaja, B. Uzochukwu, V. Vlassov, E. Weiderpass, Mamo Terefe, Henock Yebyo, H. Yimam, N. Yonemoto, M. Younis, Chuanhua Yu, Z. Zaidi, M. Zaki, Z. Zenebe, C. Murray, M. Naghavi (2017)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease StudyJAMA Oncology, 3
-
R. deLeeuw, S. Kost, J. Kakal, B. Nelson (2012)
The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the LiteratureClinical Cancer Research, 18
-
R. Harrop, N. Connolly, Irina Redchenko, J. Valle, M. Saunders, M. Ryan, K. Myers, N. Drury, S. Kingsman, R. Hawkins, M. Carroll (2006)
Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II TrialClinical Cancer Research, 12
-
P. Salama, M. Phillips, F. Grieu, M. Morris, N. Zeps, D. Joseph, C. Platell, B. Iacopetta (2009)
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 2
-
T. Maughan, R. James, D. Kerr, J. Ledermann, M. Seymour, C. Topham, C. McArdle, D. Cain, R. Stephens (2003)
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trialThe Lancet, 361
-
(2017)
Global, regional, and national cancer incidence, mortality, Research Original Investigation Vaccinia Ankara–5T4 and Cyclophosphamide for Metastatic Colorectal Cancer E8 JAMAOncology -
M. Scurr, K. Ladell, M. Besneux, A. Christian, T. Hockey, K. Smart, Hayley Bridgeman, R. Hargest, S. Phillips, M. Davies, David Price, A. Gallimore, A. Godkin (2013)
Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3− T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cellsMucosal Immunology, 7
-
E. Tran, M. Ahmadzadeh, Yong-Chen Lu, A. Gros, S. Turcotte, P. Robbins, J. Gartner, Zhili Zheng, Yong Li, Satyajit Ray, J. Wunderlich, R. Somerville, S. Rosenberg (2015)
Immunogenicity of somatic mutations in human gastrointestinal cancersScience, 350
-
J. Gulley, R. Madan, J. Schlom (2011)
Impact of tumour volume on the potential efficacy of therapeutic vaccines.Current oncology, 18 3
-
P. Southall, G. Boxer, K. Bagshawe, N. Hole, M. Bromley, P. Stern (1990)
Immunohistological distribution of 5T4 antigen in normal and malignant tissues.British Journal of Cancer, 61
-
T. Starzyńska, V. Rahi, P. Stern (1992)
The expression of 5T4 antigen in colorectal and gastric carcinoma.British Journal of Cancer, 66
-
R. Harrop, F. Chu, N. Gabrail, S. Srinivas, D. Blount, A. Ferrari (2013)
Vaccination of castration-resistant prostate cancer patients with TroVax (MVA–5T4) in combination with docetaxel: a randomized phase II trialCancer Immunology, Immunotherapy, 62
-
B. Vogelstein, N. Papadopoulos, V. Velculescu, Shibin Zhou, L. Diaz, K. Kinzler (2013)
Cancer Genome LandscapesScience, 339
-
P. Correale, M. Rotundo, C. Botta, M. Vecchio, C. Ginanneschi, A. Licchetta, R. Conca, S. Apollinari, F. Luca, P. Tassone, P. Tagliaferri (2011)
Tumor Infiltration by T Lymphocytes Expressing Chemokine Receptor 7 (CCR7) Is Predictive of Favorable Outcome in Patients with Advanced Colorectal CarcinomaClinical Cancer Research, 18
-
R. Harrop, M. Ryan, K. Myers, Irina Redchenko, S. Kingsman, M. Carroll (2006)
Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediatedCancer Immunology, Immunotherapy, 55
-
James Curtin, M. Candolfi, T. Fakhouri, Chunyan Liu, A. Alden, Matthew Edwards, P. Lowenstein, M. Castro (2008)
Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical TrialsPLoS ONE, 3
-
Takuro Saito, H. Nishikawa, H. Wada, Yuji Nagano, D. Sugiyama, K. Atarashi, Y. Maeda, M. Hamaguchi, N. Ohkura, E. Sato, Hirotsugu Nagase, J. Nishimura, Hirofumi Yamamoto, S. Takiguchi, T. Tanoue, W. Suda, H. Morita, M. Hattori, K. Honda, M. Mori, Y. Doki, S. Sakaguchi (2016)
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancersNature Medicine, 22
-
Miriam Koopman, G. Kortman, L. Mekenkamp, M. Ligtenberg, N. Hoogerbrugge, N. Antonini, C.J.A. Punt, J. Krieken (2009)
Deficient mismatch repair system in patients with sporadic advanced colorectal cancerBritish Journal of Cancer, 100
-
S. Clarke, G. Betts, A. Plant, K. Wright, T. El-shanawany, R. Harrop, J. Torkington, Brian Rees, Geraint Williams, A. Gallimore, A. Godkin (2006)
CD4+CD25+FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal CancerPLoS ONE, 1
- Publisher
- American Medical Association
- Copyright
- Copyright 2017 Scurr M et al. JAMA Oncology.
- ISSN
- 2374-2437
- eISSN
- 2374-2445
- DOI
- 10.1001/jamaoncol.2017.2579
- pmid
- 28880972
- Publisher site
- See Article on Publisher Site
Abstract
This randomized clinical trial assesses the effect of modified vaccinia Ankara–5T4, metronomic low-dose cyclophosphamide, or a combination of both treatments on antitumor immunity in patients with metastatic colorectal cancer.
Journal
JAMA Oncology – American Medical Association
Published: Oct 7, 2017